Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate.
Chaplin
David J
DJ
Oxigene Inc, Watertown, MA 02472, USA. dchaplin@oxigene.com
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D050257:Tubulin Modulators
D000972:Antineoplastic Agents, Phytogenic; D013267:Stilbenes; D050257:Tubulin Modulators; C058728:fosbretabulin